King Aaron, Rajpura Jigar, Liang Yuanjie, Paprocki Yurek, Uzoigwe Chioma
MedFirst Primary Care, San Antonio, TX, USA.
Novo Nordisk, Inc., Plainsboro, NJ, USA.
Curr Med Res Opin. 2022 Nov;38(11):1831-1840. doi: 10.1080/03007995.2022.2125259. Epub 2022 Sep 29.
To evaluate incidence of stroke, myocardial infarction (MI), and peripheral artery disease (PAD) in patients with type 2 diabetes mellitus (T2DM) and assess associated health care resource utilization (HCRU) and costs in the United States.
Patients ≥18 years of age with a T2DM diagnosis, with or without incident stroke/MI/PAD, were indexed between 1 January 2012 and 31 December 2020, from the deidentified Optum Clinformatics Data Mart claims database. Incidence of stroke, MI, and PAD was evaluated in the year following T2DM. HCRU and costs were measured in the 12 months following study entry in patients with T2DM + stroke, T2DM + MI, and T2DM + PAD (experimental cohorts) and compared to HCRU and costs in patients with T2DM alone (control cohorts).
Incidence of stroke, MI, and PAD in patients with T2DM was 0.9% ( = 16,034), 0.7% ( = 13,681), and 4.1% ( = 68,479), respectively. Compared to matched patients with T2DM alone, patients with T2DM + stroke/MI/PAD had significantly higher total healthcare costs in the year post-index date (T2DM + stroke: +$5962 per patient per month [PPPM]; T2DM + MI: +$7932 PPPM; T2DM + PAD: +$2652 PPPM; < .05). Patients with T2DM + stroke/MI/PAD had significantly higher mean HCRU than patients without stroke/MI/PAD in all categories measured.
Having stroke, MI, or PAD was associated with increases in HCRU and costs in patients with T2DM. Although PAD was associated with smaller per patient increases in total healthcare costs than patients with T2DM + stroke/MI, the higher frequency of incident PAD may make it more costly than MI or stroke in a large population of patients with T2DM.
评估2型糖尿病(T2DM)患者中风、心肌梗死(MI)和外周动脉疾病(PAD)的发病率,并评估美国相关医疗资源利用(HCRU)情况及成本。
2012年1月1日至2020年12月31日期间,对年龄≥18岁、患有或未患有中风/MI/PAD的T2DM诊断患者进行索引,数据来自匿名的Optum临床信息数据集市索赔数据库。在T2DM诊断后的一年中评估中风、MI和PAD的发病率。对T2DM + 中风、T2DM + MI和T2DM + PAD患者(实验组)在研究入组后的12个月内测量HCRU和成本,并与单纯T2DM患者(对照组)的HCRU和成本进行比较。
T2DM患者中风、MI和PAD的发病率分别为0.9%(n = 16,034)、0.7%(n = 13,681)和4.1%(n = 68,479)。与单纯匹配的T2DM患者相比,T2DM + 中风/MI/PAD患者在索引日期后的一年中总医疗成本显著更高(T2DM + 中风:每位患者每月增加5962美元[PPPM];T2DM + MI:每位患者每月增加7932美元PPPM;T2DM + PAD:每位患者每月增加2652美元PPPM;P <.05)。在所有测量类别中,T2DM + 中风/MI/PAD患者的平均HCRU显著高于无中风/MI/PAD的患者。
中风、MI或PAD与T2DM患者的HCRU增加和成本增加相关。虽然与T2DM + 中风/MI患者相比,PAD患者每位患者的总医疗成本增加幅度较小,但在大量T2DM患者中,PAD的更高发病率可能使其比MI或中风成本更高。